Nintedanib (Ofev®)
Nintedanib (Ofev®) indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Rapid Review
| Commenced | Completed | Outcome |
| 30/01/2015 | 18/02/2015 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 10/09/2015 | 22/02/2016 | Reimbursement Not Recommended at the Submitted Price |
June 2017
The HSE has approved reimbursement following confidential price negotiations.